Editas Medicine
Cambridge
About Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $931.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2023)
- Ticker: nasdaq:EDIT
- Website: editasmedicine.com
- Phone: (617) 401-9000
Industries & Categories
Biotechnology, Genetics, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/editas-medicine-8301 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.